SG11201908911QA - Modified mri contrast agents and uses thereof - Google Patents

Modified mri contrast agents and uses thereof

Info

Publication number
SG11201908911QA
SG11201908911QA SG11201908911QA SG11201908911QA SG 11201908911Q A SG11201908911Q A SG 11201908911QA SG 11201908911Q A SG11201908911Q A SG 11201908911QA SG 11201908911Q A SG11201908911Q A SG 11201908911QA
Authority
SG
Singapore
Prior art keywords
california
international
san diego
contrast agents
mri contrast
Prior art date
Application number
Other languages
English (en)
Inventor
Clare L M Leguyader
Nathan C Gianneschi
Cassandra E Callmann
Matthew P Thompson
Treffly Ditri
Paul A Bertin
Original Assignee
Univ California
Vybyl Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Vybyl Holdings Inc filed Critical Univ California
Publication of SG11201908911QA publication Critical patent/SG11201908911QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
SG11201908911Q 2017-04-27 2018-04-25 Modified mri contrast agents and uses thereof SG11201908911QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762491159P 2017-04-27 2017-04-27
PCT/US2018/029271 WO2018200615A2 (fr) 2017-04-27 2018-04-25 Produits de contraste pour irm modifiés et leurs utilisation

Publications (1)

Publication Number Publication Date
SG11201908911QA true SG11201908911QA (en) 2019-11-28

Family

ID=63920047

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201908911Q SG11201908911QA (en) 2017-04-27 2018-04-25 Modified mri contrast agents and uses thereof

Country Status (9)

Country Link
US (1) US20200046859A1 (fr)
EP (1) EP3615088A4 (fr)
JP (1) JP2020517584A (fr)
KR (1) KR20190135500A (fr)
CN (1) CN110582306A (fr)
AU (1) AU2018258345A1 (fr)
CA (1) CA3057976A1 (fr)
SG (1) SG11201908911QA (fr)
WO (1) WO2018200615A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018002514A (es) * 2015-09-22 2018-08-15 Univ California Citotoxinas modificadas y su uso terapeutico.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4011684A1 (de) * 1990-04-06 1991-10-10 Schering Ag Dtpa-monoamide, diese verbindungen enthaltende pharmazeutische mittel, ihre verwendung und verfahren zu deren herstellung
JP3404787B2 (ja) * 1993-03-12 2003-05-12 三菱ウェルファーマ株式会社 新規ジエチレントリアミンペンタ酢酸誘導体、該誘導体と金属原子との錯化合物、及び該錯化合物を含む診断剤
CA2247620A1 (fr) * 1996-04-01 1997-10-09 Epix Medical, Inc. Agents de contraste bioactives destines a l'imagerie
DE19652387A1 (de) * 1996-12-04 1998-06-10 Schering Ag Macrocyclische Metallkomplexcarbonsäuren, ihre Verwendung sowie Verfahren zu ihrer Herstellung
US20030021750A1 (en) * 2001-04-04 2003-01-30 Bakan Douglas A. Novel functional agents for magnetic resonance imaging
US20110165089A1 (en) * 2005-03-09 2011-07-07 Japan Science And Technology Agency Complex Compound and MRI Probe Made of Same
WO2008144728A1 (fr) * 2007-05-21 2008-11-27 Bracco Imaging S.P.A. Conjugués qui se lient à une protéine sanguine telle que la sérum albumine humaine et des procédés les utilisant dans des applications diagnostiques et thérapeutiques

Also Published As

Publication number Publication date
AU2018258345A1 (en) 2019-10-17
JP2020517584A (ja) 2020-06-18
WO2018200615A3 (fr) 2019-01-10
EP3615088A2 (fr) 2020-03-04
KR20190135500A (ko) 2019-12-06
WO2018200615A2 (fr) 2018-11-01
CA3057976A1 (fr) 2018-11-01
EP3615088A4 (fr) 2021-01-27
US20200046859A1 (en) 2020-02-13
CN110582306A (zh) 2019-12-17

Similar Documents

Publication Publication Date Title
SG11201811432WA (en) Rna for cancer therapy
SG11201909949XA (en) Targeted immunotolerance
SG11201908179UA (en) Aryl cyclopropyl-amino-isoquinolinyl amide compounds
SG11201903867YA (en) Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
SG11201809082WA (en) Nlrp3 modulators
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201805645QA (en) Lsd1 inhibitors
SG11201808682XA (en) Silicone atoms containing ivacaftor analogues
SG11201804506RA (en) Systems and methods for rendering multiple levels of detail
SG11201807025SA (en) Crispr/cas systems for c-1 fixing bacteria
SG11201807279QA (en) Binding proteins and methods of use thereof
SG11201811643TA (en) Compounds and methods for modulating rna function
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201907023UA (en) Method of reducing neutropenia
SG11201807421TA (en) The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201809751XA (en) Egfr inhibitor compounds
SG11201407343XA (en) Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201808676RA (en) Methods of treating pediatric cancers
SG11201804412SA (en) Dimeric contrast agents
SG11201906973TA (en) Multiple transgene recombinant adenovirus
SG11201407372UA (en) Nampt inhibitors
SG11201909837YA (en) Methods for treating lung disorders
SG11201908114UA (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors